FDA clears first POC (point-of-care) oral test for opiates
This article was originally published in Clinica
OraSure Technologies has gained FDA 510(k) clearance to market in the US what is claimed to be the first point-of-care (POC) test system that can detect drugs of abuse in a sample of oral fluid.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.